Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

NCT ID: NCT05613205

Last Updated: 2025-01-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 97 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-28
• Study Completion Date: 2024-04-02

Brief Summary

A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).

The purpose of this first-time-in-human study is to evaluate the safety and immunogenicity profile of a low and a full dose of the investigational vaccine, formulated with or without adjuvant, administered in 2 doses, 24 weeks apart, in healthy adults 18 to 50 years of age in Europe.

Conditions

Typhoid Fever

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Step 1a: Low dose TYP04A vaccine without Alum

Participants received low dose of the TYP04A vaccine without Alum intramuscularly on Day 1 and Day 169.

Group Type: EXPERIMENTAL

TYP04A Low Dose without Alum investigational vaccine

Intervention Type: BIOLOGICAL

2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Step 1b: Low dose TYP03A vaccine with Alum

Participants received low dose of the TYP03A vaccine with Alum intramuscularly on Day 1 and Day 169.

Group Type: EXPERIMENTAL

TYP03A Low Dose with Alum investigational vaccine

Intervention Type: BIOLOGICAL

2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Step 2: Full dose TYP04B vaccine without Alum

Participants received full dose of the TYP04B vaccine without Alum intramuscularly on Day 1 and day 169.

Group Type: EXPERIMENTAL

TYP04B Full Dose without Alum investigational vaccine

Intervention Type: BIOLOGICAL

2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Step 2: Full dose TYP03B vaccine with Alum

Participants received full dose of the TYP03B vaccine with Alum intramuscularly on Day 1 and day 169.

Group Type: EXPERIMENTAL

TYP03B Full Dose with Alum investigational vaccine

Intervention Type: BIOLOGICAL

2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Control: TYPHIM VI and BOOSTRIX vaccine

Participants received TYPHIM VI as comparator intramuscularly on Day 1, and BOOSTRIX as comparator on Day 169.

Group Type: ACTIVE_COMPARATOR

Sanofi Pasteur's Typhoid Vi polysaccharide vaccine

Intervention Type: BIOLOGICAL

1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.

GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine

Intervention Type: BIOLOGICAL

1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.

Interventions

TYP04A Low Dose without Alum investigational vaccine

2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention Type: BIOLOGICAL

TYP04B Full Dose without Alum investigational vaccine

2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention Type: BIOLOGICAL

TYP03A Low Dose with Alum investigational vaccine

2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention Type: BIOLOGICAL

TYP03B Full Dose with Alum investigational vaccine

2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.

Intervention Type: BIOLOGICAL

Sanofi Pasteur's Typhoid Vi polysaccharide vaccine

1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.

Intervention Type: BIOLOGICAL

GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine

1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.

Intervention Type: BIOLOGICAL

Other Intervention Names

Typhoid and Paratyphoid A conjugate low dose without adjuvant vaccine; Typhoid and Paratyphoid A conjugate full dose without adjuvant vaccine; Adjuvanted Typhoid and Paratyphoid A conjugate low dose vaccine; Adjuvanted Typhoid and Paratyphoid A conjugate full dose vaccine; TYPHIM VI; BOOSTRIX

Eligibility Criteria

Inclusion Criteria

• Participants who, in the opinion of the Investigator, can and will comply with the requirements of the Protocol (e.g., completion of the diary cards, return for follow-up visits).
• Written informed consent obtained from the participant prior to performance of any study specific procedure.
• Healthy participants as established by medical history, clinical examination, and screening laboratory investigations.
• Participant satisfying screening requirements.
• Participant seronegative for human immunodeficiency virus, hepatitis B, and hepatitis C at Screening.
• A male or female participant between, and including, 18 and 50 years of age at the time of the first study intervention administration.
• Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
• Female participants of childbearing potential may be enrolled in the study if the participant:

• has practiced adequate contraception for 1 month prior to study intervention administration, and
• has a negative pregnancy test on the day of study intervention administration, and
• has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

Exclusion Criteria

Medical conditions

• Progressive, unstable or uncontrolled clinical conditions.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
• Hypersensitivity, including allergy, to medicinal products or medical equipment whose use is foreseen in this study.
• Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
• Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
• Acute* or chronic illness, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.

*Participants with a minor illness (such as mild diarrhoea or mild upper respiratory infection) without fever may be enrolled at the discretion of the Investigator.

• Any clinically significant* haematological and/or biochemical laboratory abnormality.

*The Investigator should use his/her clinical judgement to decide which abnormalities are clinically significant.

• Confirmed positive COVID-19 test during the period starting 14 days before the first administration of study vaccines (Day -14 to Day 1).
• Any other clinical condition that, in the opinion of the Investigator, might pose additional risk to the participant due to participation in the study.
• Confirmed or suspected autoimmune diseases (e.g., vitiligo, autoimmune thyroiditis).

Prior/Concomitant therapy

• Previous administration of any type of Typhoid vaccine (Ty21a, Vi-PS, or Typhoid conjugate vaccine).
• Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study interventions during the period starting 30 days before the first administration of study vaccines (Day -30 to Day 1), or planned use during the study period.
• A vaccine not foreseen by the study protocol administered during the period starting at -14 days before the first dose (-21 days in the case of live vaccines) and ending 28 days after the last dose of study intervention administration*, with the exception of flu and COVID-19 vaccines, administered during the period starting at 7 days before and 7 days after each dose (14 days before and 14 days after in case of live vaccines).

*In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organised by public health authorities outside the routine immunisation programme, the time period described above can be reduced if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. When regulations allow, the recommended time intervals for administration of these vaccines are at least 7 days before or 7 days after (at least 14 days before or 14 days after in case of live vaccines) each dose of study intervention administration.

• Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).
• Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention or planned administration during the study period.
• Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug/invasive medical device).

Other exclusions

• History of travel to countries of Asia that are considered endemic* for enteric fever in the last 3 years.

*this also includes travel during study duration.

• Pregnant or lactating female.
• Female participants planning to become pregnant or planning to discontinue contraceptive precautions.
• History of or current chronic alcohol consumption and/or drug abuse.
• Any study personnel or immediate dependents, family, or household member.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Biological E. Limited

UNKNOWN

Sponsor Role: collaborator

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Edegem, , Belgium

Countries

Belgium

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2021-002029-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

205480

Identifier Type: -

Identifier Source: org_study_id